Clinical trials: Ocular Hypertension (OHT)
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Ocular Hypertension, Glaucoma
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
This cross-over study will investigate the efficacy and safety of BIMMD and TUDPF in a clinical setting.
- Trial name
- SPORTII (NCT02471105)
- Testing
- Preserved Bimatoprost 0.01%, Tafluprost Unit Dose Preservative Free 15microgram/ml
- Where
- 7 sites in Austria, Belgium and 3 more
- Volunteers
- 67 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Primary Open-angle Glaucoma (POAG), Ocular Hypertension (OHT)
Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension
The primary purpose of this study is to investigate the safety and efficacy of bilateral DWT in subjects with POAG or OHT compared to active and sham controls.
- Trial name
- NCT02226094
- Testing
- DWT device dose A, Ellex Tango SLT machine, DWT device dose B
- Where
- 2 sites in Philippines
- Volunteers
- 35 people
- Sponsor
- OcuTherix, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00051142
- Testing
- Travoprost, Latanoprost
- Where
- United States
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
- Trial name
- NCT05335122
- Testing
- OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
- Where
- 30 sites in United States
- Volunteers
- 83 people
- Sponsor
- Ocular Therapeutix, Inc.
Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Visual Outcomes of Vivity in Patients With Well Controlled Glaucoma
Glaucoma is a progressive optic neuropathy that results in a loss of contrast sensitivity and visual field if not detected and treated.
- Trial name
- NCT05075226
- Testing
- Vivity Extended Depth of Focus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Open-Angle, Ocular Hypertension
Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
This study will evaluate assessments from the Goniometric Lens compared with those from anterior segment imaging in patients with open-angle glaucoma (OAG) and/or ocular hypertension (OHT).
- Trial name
- NCT01540370
- Testing
- No Treatment
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension…
- Trial name
- TRITON (NCT03850782)
- Testing
- Bimatoprost (SR)
- Where
- 108 sites in United States, Argentina and 14 more
- Volunteers
- 515 people
- Sponsor
- AbbVie
Open-Angle Glaucoma, Ocular Hypertension
Efficacy of Changing to TRAVATAN® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.
- Trial name
- NCT01493427
- Testing
- Travoprost 0.004%
- Volunteers
- 202 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Oular Hypertension
Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to evaluate the safety and intraocular-lowering efficacy of anecortave acetate depot when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in…
- Trial name
- NCT00691717
- Testing
- Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Alcon Research
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity
The purpose of this research study is to compare the effect of Netarsudil and Timolol on eye pressure and blood vessels of the back of the eye.
- Trial name
- NCT04064918
- Testing
- Netarsudil 0.02% QD, Timolol maleate 0.5% BID
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Diego
Glaucoma, Glaucoma, Open-Angle
Impact of Self-tonometry on Glaucoma Treatment Decision.
Self-tonometry with iCare Home is performed by one hundred patients annually at Sankt Erik's Eye Hospital. The investigators want to evaluate the impact that self-tonometry results have on the clinician's choice of glaucoma…
- Conditions
- Glaucoma, Glaucoma, Open-Angle, OHT - Ocular Hypertension, Glaucoma Capsulare
- Trial name
- NCT04888156
- Testing
- Unchanged treatment, Changed treatment
- Where
- Sweden
- Volunteers
- 133 people
- Sponsor
- St. Erik Eye Hospital
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss.
- Trial name
- NCT07408154
- Testing
- Direct Selective laser Trabeculoplasty
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Medical University of South Carolina
Ocular Hypertension
FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular Hypertension
A PHASE 1/2A, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF FM101 IN PATIENTS WITH OCULAR HYPERTENSION, AND TO ASSESS THE RELATIVE BIOAVAILABILITY OF THE…
- Trial name
- NCT04585100
- Testing
- FM101 tablet, FM101 oral solution, FM101 150 mg
- Where
- 5 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Future Medicine
Glaucoma, Ocular Hypertension
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
- Trial name
- JUPITER (NCT01895972)
- Testing
- Latanoprostene bunod
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Bausch & Lomb Incorporated
Open-Angle Glaucoma, Ocular Hypertension
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine fixed combination in lowering intraocular pressure (IOP) relative to each of its individual active constituents instilled concomitantly…
- Trial name
- NCT01309204
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, Vehicle, Brinzolamide 1% ophthalmic suspension
- Volunteers
- 1,184 people
- Sponsor
- Alcon Research
Glaucoma, Open-angle, Ocular Hypertension (OHT)
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone
- Conditions
- Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
- Trial name
- NCT06848946
- Testing
- iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Glaukos Corporation
Ocular Hypertension, Open Angle Glaucoma
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT07082816
- Testing
- Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
- Where
- 30 sites in United States
- Volunteers
- 489 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open-Angle Glaucoma
Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP).
- Trial name
- NCT00698945
- Testing
- Istalol and Optive, Alphagan
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bp Consulting, Inc